Structured abstract
Background Plasma low-density lipoprotein (LDL)-cholesterol is positively associated with coronary artery disease risk while biliary cholesterol promotes gallstone formation.
Objectives We tested the hypothesis that different plasma LDL-cholesterol lowering pathways have distinct effects on biliary cholesterol and thereby risk of gallstone disease.
Methods This Mendelian randomization (MR) study used data from the UK Biobank (30,547 gallstone disease cases/336,742 controls), FinnGen (34,461 cases/301,383 controls) and Biobank Japan (9,305 cases/168,253 controls). First, drug-target MR and colocalization analyses were performed to investigate plasma LDL-cholesterol lowering therapies on gallstone disease. Second, clustered MR and pathway analyses were performed to identify distinct mechanisms underlying the association of plasma LDL-cholesterol with gallstone disease.
Results For a 1-standard deviation reduction in plasma LDL-cholesterol, genetic mimics of statins were associated with lower risk of gallstone disease (odds ratio 0.72 [95% confidence interval 0.62, 0.83]) but PCSK9 inhibitors and mipomersen were associated with higher risk (1.11 [1.03, 1.19] and 1.23 [1.13, 1.35]). The association for statins was supported by colocalization (posterior probability 98.7%). Clustered MR analyses identified variant clusters showing opposing associations of plasma LDL-cholesterol with gallstone disease, with evidence for ancestry-and sex-specific associations. Among variants predicting lower plasma LDL-cholesterol, those associated with lower risk of gallstone disease were mapped to glycosphingolipid biosynthesis pathway, while those associated with higher risk were mapped to pathways relating to plasma lipoprotein assembly, remodelling, and clearance and ATP-binding cassette transporters.
Conclusions Different plasma LDL-cholesterol lowering pathways may have opposing effects on risk of gallstone disease. Notably, statins may reduce risk of gallstone disease.
Condensed abstract We hypothesized that different plasma LDL-cholesterol lowering pathways have distinct effects on risk of gallstone disease. We performed drug-target and clustered Mendelian randomization (MR) analyses, using data from the UK Biobank, FinnGen and Biobank Japan. Genetic mimics of statins were associated with lower risk of gallstone disease, but PCSK9 inhibitors and mipomersen were associated with higher risk. Clustered MR identified variant clusters showing opposing associations of plasma LDL-cholesterol with gallstone disease. This genetic study supports that different plasma LDL-cholesterol lowering pathways have opposing effects on risk of gallstone disease and statins may reduce risk of gallstone disease.
Competing Interest Statement
DG is employed part-time by Novo Nordisk, outside of this work. The remaining authors declared no conflict of interest.
Funding Statement
GY is supported by the Bau Tsu Zung Bau Kwan Yeu Hing Research and Clinical Fellowship from the University of Hong Kong. AMM is funded by the EU/EFPIA Innovative Medicines Initiative Joint Undertaking BigData@Heart grant 116074. DG is supported by the British Heart Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial College. SB is supported by the Wellcome Trust (225790/Z/22/Z) and the United Kingdom Research and Innovation Medical Research Council (MC_UU_00002/7). This research was supported by British Heart Foundation (RG/13/13/30194; RG/18/13/33946), BHF Cambridge CRE (RE/18/1/34212), and the National Institute for Health Research Cambridge Biomedical Research Centre (NIHR203312). The views expressed are those of the authors and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care. The funders had no role in the study design, analyses, or interpretation of results. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been conducted using the UK Biobank Resource (Application number 98032). The UK Biobank obtained ethical approval from the North West Multi-centre Research Ethics Committee, and the participants provided written informed consent. The analysis of publicly available summary statistics does not require ethical approval.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding GY is supported by the Bau Tsu Zung Bau Kwan Yeu Hing Research and Clinical Fellowship from the University of Hong Kong. AMM is funded by the EU/EFPIA Innovative Medicines Initiative Joint Undertaking BigData@Heart grant 116074. DG is supported by the British Heart Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial College. SB is supported by the Wellcome Trust (225790/Z/22/Z) and the United Kingdom Research and Innovation Medical Research Council (MC_UU_00002/7). This research was supported by British Heart Foundation (RG/13/13/30194; RG/18/13/33946), BHF Cambridge CRE (RE/18/1/34212), and the National Institute for Health Research Cambridge Biomedical Research Centre (NIHR203312). The views expressed are those of the authors and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care. The funders had no role in the study design, analyses, or interpretation of results. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission.
Disclosures DG is employed part-time by Novo Nordisk, outside of this work. The remaining authors declared no conflict of interest.
Tweet: Trans-biobank Mendelian randomization analyses support that different plasma LDL-cholesterol lowering pathways have distinct and opposing effects on risk of gallstone disease. Statins may reduce risk of gallstone disease. #LDL, #Gallstones, #Mendelian randomization
Data availability
This study has been conducted using the UK Biobank Resource under Application number 98032. Summary-level data analyzed are available in the website http://csg.sph.umich.edu/willer/public/glgc-lipids2021/ for GLGC, https://www.finngen.fi/en/access_results for FinnGen, https://pheweb.jp/downloads for Biobank Japan, and http://www.cardiogramplusc4d.org/data-downloads/ for CARDIoGRAMplusC4D Consortium. The R code for data analysis is shared in the GitHub https://github.com/YANGGYEMMA/LDL_and_gallstones.
Abbreviations
- ABCG5/8
- adenosine triphosphate-binding cassette transporters G5/8
- ATP
- adenosine triphosphate
- CAD
- coronary artery disease
- eQTL
- expression quantitative trait locus
- FUMA
- Functional Mapping and Annotation
- GLGC
- Global Lipids Genetics Consortium
- GWAS
- genome-wide association studies
- ICD
- International Classification of Diseases
- IVW
- inverse variance weighting
- LDL
- low-density lipoprotein
- MI
- myocardial infarction
- MR
- Mendelian randomization
- PCSK9
- proprotein convertase subtilisin/kexin type 9
- RCT
- randomized controlled trial
